News by subject: Clinical Study

Curium, a world leader in nuclear medicine, announced today the positive results of the multi-center, open-label, Phase 2 SOLAR study of Copper Cu 64 PSMA I&T in patients with histologically-proven metastatic prostate cancer. The study has met the...

Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") , a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has...

-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- qEEG study was conducted in healthy...

Biogen Inc. and Sage Therapeutics, Inc. (Nasdaq:...

Medicenna Therapeutics Corp. ("Medicenna" or "the Company") , a clinical-stage immunotherapy company, announced today that it will host a conference call and live webcast on August 9, 2023 at 8:30AM ET to provide a clinical update from the Phase 1/2...

New research looking at the mental health and eating behaviours of patients 1-year after bariatric surgery has found that a short, 7-session telephone cognitive behavioural therapy (Tele-CBT) intervention is helpful in reducing symptoms of...

A recent survey conducted by Essilor®, part of EssilorLuxottica a leading global eyecare and eyewear provider, revealed that children's eye health and vision are often overlooked by parents amidst the many other concerns they face.1 The survey, which...

Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immune-based...

IntelGenx Corp.  (the "Company" or "IntelGenx") today announced that it has completed patient enrollment in the ongoing Montelukast VersaFilm® Phase 2a ("BUENA") clinical trial in patients with mild to moderate Alzheimer's Disease ("AD"). The...

Helius Medical Technologies, Inc. ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the expansion of the...

Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that it has enrolled a total of 69 patients for the Company's Tigris trial, a Phase 3...

IntelGenx Corp.  (the "Company" or "IntelGenx") today announced the execution of a Research Grant Agreement with Karolinska University Hospital and that the manufacturing of both active and placebo films are underway in preparation for a planned...

The AIDS Clinical Trials Group (ACTG), a global clinical trials network focused on HIV, tuberculosis, hepatitis B and emerging infectious diseases, today announced the publication of "Pitavastatin to Prevent Cardiovascular Disease in HIV Infection"...

Curium, a world leader in nuclear medicine, announced today the publication of the results of its European, multicenter, prospective cross-over clinical trial which compared [18F] piflufolastat ([18F]DCFPyL) versus [18F]fluoromethylcholine PET/CT in...

PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") , a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including MDMA), is thrilled that ? following pre-submission meetings held...

NurExone Biologic Inc. (NRX.V) ("NurExone" or the "Company") is pleased to announce significant advancements in extracellular vesicles (EVs) functionality. Leveraging its proprietary and patented 3D-Flow production, the Company has achieved...

-- BMB-101 is a highly selective and potent 5-HT2C agonist being developed for the treatment of refractory epilepsies and other indications, such as psychosis, addiction, and impulse control disorders -- BMB-101 demonstrated an excellent safety and...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the...

Achieve Life Sciences, Inc. , today announced the publication in JAMA of the results from the Phase 3 ORCA-2 randomized placebo-controlled...

VANCOUVER, BC ? July 10, 2023 ? Praxis Spinal Cord Institute is delighted to announce the allocation of more than $4 million in grant awards to support 33 spinal cord injury (SCI) initiatives across Canada. Projects funded involve SCI translational...

Axsome Therapeutics, Inc. , a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced that it has dosed the first patient in the FOCUS Phase 3 trial of...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A....

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced results of the Company's Phase 3 clinical trial...

Spectral Medical Inc. ("Spectral" or the "Company") , a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced the opening of three new clinical trials sites, the University of Alabama at Birmingham...

Small...

Genenta Science , a clinical-stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors, today announced that the European Commission has...

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the U.S....

Arch Biopartners Inc., ("Arch" or the "Company") , announced today that it received a "Study May...

BetterLife Pharma Inc. ("BetterLife" or the "Company") , an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that its scientific collaborators, Drs. Vern Lewis...

Arbutus Biopharma Corporation ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the first...

Spectral Medical Inc. ("Spectral" or the "Company") , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an enrollment update on Tigris, the Company's follow-on study designed to build on...

Datacubed Health, a leading provider of innovative technology solutions for clinical research, is proud to announce its partnership with renowned medical practitioner Eugene Lipov, M.D. in a pioneering study focused on the extent of physiologic...

Triple Hair Group Inc. ("Triple Hair" or the "Company"), a company specializing in the development of innovative treatments for alopecia, is pleased to announce that it has received positive results from various preclinical safety studies on its...

Finalized Dose Escalation/Dose Exploration Trial in 77 R/R AML PatientsFavorable safety with monotherapy responses across four dose levels with no DLT in mutationally diverse and difficult to treat R/R AML PopulationsTP53MUT CR/CRh = 20% ? RASMUT...

Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that two abstracts have been accepted for poster...

Algernon Pharmaceuticals Inc.  (the "Company" or "Algernon") a Canadian clinical stage pharmaceutical development company is pleased to announce that it will present its Phase 2a Ifenprodil cough data at the 9th American Cough Conference (ACC)...

Ractigen Therapeutics, a biopharmaceutical company focused on the discovery, development, and commercialization of novel oligonucleotide therapeutics, today announced the dosing of its first patient in the Company's First in Human (FIH) clinical...

Algernon Pharmaceuticals Inc. (the "Company" or "AGN Pharma") , a Canadian clinical stage pharmaceutical development company, is pleased to advise that its subsidiary Algernon NeuroScience (AGN Neuro), has successfully completed dosing of the third...

NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for global marketsLotus Pharmaceuticals will acquire...

Spectral Medical Inc. ("Spectral" or the "Company") , a late stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an enrollment update on Tigris, the Company's follow-on study designed to build on...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company's U.S. Food & Drug...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the...

ORCA-3 demonstrated statistically significant topline results in primary and secondary smoking cessation endpoints for both 6- and 12-week cytisinicline treatment durations compared to placebo Cytisinicline demonstrated 6x increase in odds of...

AiViva Biopharma Inc., a clinical-stage biotechnology company, announced that it has begun a Phase 1 trial and completed dosing the first cohort of patients diagnosed with wet age-related macular degeneration (wAMD), and/or diabetic macular edema...

Data demonstrated that AAV vectors expressing engineered immunomodulatory interferon (IFN) cytokine payloads led to: Rapid and selective reduction in tumor size in high-grade glioma (HGG) organoidsTumor regression and significantly prolonged survival...

Revive Therapeutics Ltd. ("Revive" or the "Company") , a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today an update on the Company's U.S. Food & Drug...

Salipro Biotech AB and DyNAbind GmbH, two leading biotech companies, announced today the achievement of a key milestone from their collaboration aimed to revolutionize drug discovery against difficult-to-drug targets. The collaboration combines the...

? Tuspetinib Dose Escalation and Dose Exploration Trial Completed and Delivered Clinical Responses as Monotherapy Over Four Dose Levels in Very Difficult to Treat AML Patient Populations ? ? Doublet of Tuspetinib and Venetoclax Dosing Underway for...

Theratechnologies Inc. ("Theratechnologies" or the "Company") , a biopharmaceutical company focused on the development and commercialization of innovative...

XORTX Therapeutics Inc. ("XORTX" or the "Company") , a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce completion of a positive and constructive Type D...